Jeffrey Clement
Nephrology · Providence, RINPI 1164420576
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 292 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,248 and has fallen 95.0% since, to $112 in 2024.
Across 292 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$998
- Vifor Pharma, Inc.$943
- Otsuka America Pharmaceutical, Inc.$628
- Akebia Therapeutics Inc$462
- OPKO Pharmaceuticals, LLC$402
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,09895%
- Education$3445%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 48 | $1,398 |
| Amgen(2 entities) | 23 | $998 |
| Vifor Pharma, Inc. | 54 | $943 |
| Otsuka America Pharmaceutical, Inc. | 30 | $628 |
| Akebia Therapeutics Inc | 18 | $462 |
| OPKO Pharmaceuticals, LLC | 22 | $402 |
| Bayer | 10 | $397 |
| Fresenius USA Marketing, Inc. | 11 | $351 |
| Johnson & Johnson | 8 | $334 |
| GSK | 18 | $284 |
| Aurinia Pharma U.S., Inc. | 9 | $245 |
| Daiichi Sankyo Inc. | 5 | $211 |
| Calliditas Therapeutics US Inc. | 6 | $139 |
| Boehringer Ingelheim | 2 | $126 |
| Travere Therapeutics, Inc. | 5 | $98 |
| Novartis | 5 | $89 |
| Mallinckrodt Hospital Products Inc. | 3 | $55 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Strongbridge US Inc. | 3 | $38 |
| CMP Pharma, Inc. | 1 | $27 |
| Arbor Pharmaceuticals, Inc. | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 2 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,442 in reported general payments places this provider in the 80th percentile of 45 nephrology providers in Rhode Island.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 23 | $37,981 |
| Sevelamer Carbonate | 17 | $2,212 |
| Chlorthalidone | 23 | $637 |
| Metoprolol Succinate | 15 | $470 |
| Lisinopril | 40 | $389 |
| Doxazosin Mesylate | 18 | $357 |
| Losartan Potassium | 25 | $335 |
| Amlodipine Besylate | 35 | $248 |
| Spironolactone | 12 | $97 |
| Hydrochlorothiazide | 17 | $80 |
| Furosemide | 12 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $351 | $37,98123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 45 nephrology providers in Rhode Island.
Other nephrology in Providence
- Keith BartolomeiProvidence$15K
- Elkin EstradaProvidence$11K
- Katherine DavorenProvidence$9K
- Devyani SivakumarProvidence$5K
- Muhammad LiaqatProvidence$4K
- Amol MittalProvidence$3K
- Marc WeinbergProvidence$3K
- Jonah LichtProvidence$2K
- Alay NanavatiProvidence$537
- Shijo BenjaminProvidence$491
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.